HCWB (HCW Biologics Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by HCWB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | Hing C Wong | Chief Executive Officer | Buy | — | — |
| 2026-07-31 | SCOTT T GARRETT | Director | Buy | — | — |
| 2026-07-31 | Lee Flowers | SVP of Business Development | Buy | — | — |
| 2026-05-27 | SCOTT T GARRETT | Director | Buy | — | — |
| 2026-05-27 | Hing C Wong | Chief Executive Officer | Buy | — | — |
| 2026-05-27 | Rebecca Byam | Chief Financial Officer | Buy | — | — |
| 2025-05-20 | Gary M Winer | Director | Buy | — | — |
| 2025-05-20 | Hing C Wong | Chief Executive Officer | Buy | — | — |
| 2025-05-20 | SCOTT T GARRETT | Director | Buy | — | — |
| 2025-05-09 | Gary M Winer | Director | Buy | — | — |
| 2025-05-09 | Rick S. Greene | Director | Buy | — | — |
| 2025-05-09 | Rebecca Byam | Chief Financial Officer | Buy | — | — |
| 2025-05-09 | Lee Flowers | SVP of Business Development | Buy | — | — |
| 2025-05-09 | Hing C Wong | Chief Executive Officer | Buy | — | — |
| 2025-05-09 | SCOTT T GARRETT | Director | Buy | — | — |
| 2024-06-17 | Lisa M. Giles | Director | A | — | — |
| 2024-06-17 | SCOTT T GARRETT | Director | A | — | — |
| 2024-06-17 | Gary M Winer | Director | A | — | — |
| 2024-06-17 | Rick S. Greene | Director | A | — | — |
| 2024-02-22 | Hing C Wong | Chief Executive Officer | A | — | — |
| 2024-02-22 | Lisa M. Giles | Director | A | — | — |
| 2024-02-22 | Rick S. Greene | Director | A | — | — |
| 2024-02-22 | Lee Flowers | SVP of Business Development | A | — | — |
| 2024-02-22 | SCOTT T GARRETT | Director | A | — | — |
| 2024-02-22 | Rebecca Byam | Chief Financial Officer | A | — | — |
| 2023-12-11 | Peter Rhode | See Remarks | M | — | — |
| 2023-12-11 | Lee Flowers | SVP of Business Development | M | — | — |
| 2023-11-20 | Peter Rhode | See Remarks | M | — | — |
| 2023-10-23 | Rebecca Byam | Chief Financial Officer | M | — | — |
| 2023-09-18 | Hing C Wong | Chief Executive Officer | Buy | — | — |
| 2023-09-15 | Rebecca Byam | Chief Financial Officer | Buy | — | — |
| 2023-09-15 | Gary M Winer | Director | Buy | — | — |
| 2023-09-13 | Rebecca Byam | Chief Financial Officer | Buy | — | — |
| 2023-09-12 | Gary M Winer | Director | Buy | — | — |
| 2023-09-08 | Rebecca Byam | Chief Financial Officer | Buy | — | — |
| 2023-09-07 | Rebecca Byam | Chief Financial Officer | Buy | — | — |
| 2023-09-07 | Gary M Winer | Director | Buy | — | — |
| 2023-06-15 | Gary M Winer | Director | A | — | — |
| 2023-06-15 | Rick S. Greene | Director | A | — | — |
| 2023-06-15 | Lisa M. Giles | Director | A | — | — |
| 2023-06-15 | SCOTT T GARRETT | Director | A | — | — |
| 2023-06-09 | Rebecca Byam | Chief Financial Officer | Buy | — | — |
| 2023-06-09 | Lee Flowers | SVP of Business Development | MIXED | — | — |
| 2023-06-08 | Rebecca Byam | Chief Financial Officer | Buy | — | — |
| 2023-06-07 | Rebecca Byam | Chief Financial Officer | Buy | — | — |
| 2023-06-02 | Hing C Wong | Chief Executive Officer | Buy | — | — |
| 2023-06-01 | Gary M Winer | Director | Buy | — | — |
| 2023-06-01 | Hing C Wong | Chief Executive Officer | Buy | — | — |
| 2023-05-31 | Rebecca Byam | Chief Financial Officer | Buy | — | — |
| 2023-05-24 | Rebecca Byam | Chief Financial Officer | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 125,845 | — |
| — | Director | 45,895 | — |
| — | Chief Financial Officer | 9,541 | — |
| — | SVP of Business Development | 8,691 | — |
| — | Director | 679 | — |
| — | Director | 344 | — |
| — | See Remarks | 323 | — |
| — | VP of Development | 181 | — |
| — | Director | 149 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HCWB quote page; the site-wide leaderboard is on the insider transactions hub.